|Aglaia BioMedical Ventures||Partner||The Netherlands|
Thinking of the exit scenario to shape a biotech start-up at its first steps: Which model for which term of exit?
Mark Krul, PhD, Partner at Aglaia BioMedical Ventures, The Netherlands
Mark has been involved in anticancer drug development since 1993 and has a background in molecular biology and immunology. Before founding Aglaia BioMedical Ventures in 2003 he was Program Director of the NDDO Research Foundation. He held several positions at NDDO Oncology BV (formerly the EORTC New Drug Development Office) with respect to oncology drug development strategies (1997-2002). From 1993 till 1997 Mark has been Research Manager of the European Cancer Center and headed the Department of Molecular Virology at the National Institute of Public Health and Environmental Protection from 1989 till 1993.
After the successful first fund, The Fund Manager – Aglaia BioMedical Ventures – is currently investing from its second fund: Aglaia Oncology Fund II